Ascentage Pharma Group International

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 16:08:10 15/01/2026 HKT			5-day change	1st Jan Change
53.40 ^HKD	-2.02%		-1.66%	+2.20%

01:05pm	Ascentage Pharma Group International Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 02:15 PM
01-07	Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	MT

Ascentage Pharma Group International says phase III study of olverembatinib cleared by FDA, EMA

Published on 12/05/2025 at 09:36 am HKT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ascentage Pharma Group International

01:05pm	Ascentage Pharma Group International Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 02:15 PM
01-07	Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	MT
01-07	Ascentage Pharma Gets FDA's IND Clearance for APG-3288	MT
01-07	Ascentage Pharma Group International Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288	CI
12-30	Ascentage Pharma Group International Announces Board and Committee Appointments and Establishment of Research and Development Committee, Effective December 26, 2025	CI
12-09	Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%	CI
12-09	Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP	CI
12-09	Ascentage Pharma Group International Presents Updated Data for Ascentage Pharma?S Olverembatinib in Second-Line Cml-Cp Showing Encouraging Potential for Early-Line Treatment	CI
12-08	Ascentage Pharma Group International Presents Encouraging Data from Phase Ib/Ii Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances	CI
12-06	Ascentage Pharma Group International Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology Annual Meeting	CI
12-05	Ascentage Pharma Group International Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ All Cleared by US FDA and EMA	CI
12-05	Ascentage Pharma Wins U.S., E.U. Clearance for Global Phase 3 Olverembatinib Study	MT
12-05	Ascentage Pharma Group International says phase III study of olverembatinib cleared by FDA, EMA	RE
11-25	Ascentage Pharma Group International Inc. Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data Inastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy	CI
11-04	Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of Olverembatinib, Lisaftoclax, APG-5918	CI
16/10/25	Certain Ordinary Shares of Ascentage Pharma Group International are subject to a Lock-Up Agreement Ending on 16-OCT-2025.	CI
07/10/25	Ascentage Pharma Group International to Participate in Three Upcoming Investor Conferences in October 2025	CI
04/09/25	Ascentage Pharma Group International Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 04:00 PM
21/08/25	Sector Update: Health Care Stocks Fall Premarket Thursday	MT
21/08/25	Sector Update: Health Care	MT
21/08/25	Ascentage Pharma Group International Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/08/25	Ascentage Pharma Swings to H1 Loss, Revenue Falls	MT
21/08/25	Ascentage Pharma Swings to H1 Loss on Weaker Revenue	MT
21/08/25	Ascentage Pharma Group International posts HY net loss was RMB590.8 million	RE
18/08/25	Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday	MT

Chart Ascentage Pharma Group International

Duration

Period

Chart Ascentage Pharma Group International

6855: Dynamic Chart

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Employees

605

Sector

Biotechnology & Medical Research

Calendar

04-01 - Q4 2025 Earnings Release (Projected)

More about the company